Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intravenous Lidocaine on Post-extubation Laryngospasm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesia score are I or II~* Undergo for laparoscopic cholecystectomy~Exclusion Criteria:~* Patient's refusal~* History of upper respiratory tract infection (URTI) within 2 weeks~* Persistent type of hyper-reactive airway or asthma~* History of airway surgery~* History of gastro-esophageal reflex disease (GERD)~* Currently receiving sedating or analgesic medication~* Currently receiving the following medications:~  * Fluvoxamine~ * Erythromycin and Itraconazole~ * β -blocker or Cimetidine~* History of Lidocaine Allergy~* History of epilepsy disorder~* Pregnant or breastfeeding women~* History of Heavy Smoking ( a smoker with a daily cigarettes consumption of more than 20 pieces~* History of increased salivation by a disease or medication~* History of difficult intubation~* Two or more attempts of intubation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Lidocaine 1% was prepared in 10 mL syringe= 10 mg/mL, dosage was 1mg/kg, one bolus or 10 mL/kg, with range of 2mg could be added or missed. The maximum dose is 100 mg for patients with weight of more than 100
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline was prepared in 10 mL syringe, dosage was 1 mL/10 kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).